These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 21091799

  • 21. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
    Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L.
    Cancer; 2008 Aug 15; 113(4):710-6. PubMed ID: 18543328
    [Abstract] [Full Text] [Related]

  • 22. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I.
    Aktuelle Urol; 2009 Mar 15; 40(2):91-9. PubMed ID: 19214951
    [Abstract] [Full Text] [Related]

  • 23. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.
    Ehdaie B, Sylvester R, Herr HW.
    Eur Urol; 2013 Oct 15; 64(4):579-85. PubMed ID: 23711538
    [Abstract] [Full Text] [Related]

  • 24. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov 15; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 25. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May 15; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 26. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
    Lammers RJ, Witjes JA.
    Expert Rev Anticancer Ther; 2010 Dec 15; 10(12):1903-16. PubMed ID: 21110757
    [Abstract] [Full Text] [Related]

  • 27. Management of BCG failures in superficial bladder cancer: a review.
    Witjes JA.
    Eur Urol; 2006 May 15; 49(5):790-7. PubMed ID: 16464532
    [Abstract] [Full Text] [Related]

  • 28. Intravesical therapy for bladder cancer.
    Williams SK, Hoenig DM, Ghavamian R, Soloway M.
    Expert Opin Pharmacother; 2010 Apr 15; 11(6):947-58. PubMed ID: 20205607
    [Abstract] [Full Text] [Related]

  • 29. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb 15; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 30. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
    Uekado Y, Kohjimoto Y, Iba A, Kikkawa K, Shintani Y, Shinka T.
    Hinyokika Kiyo; 2006 Jun 15; 52(6):439-44. PubMed ID: 16848357
    [Abstract] [Full Text] [Related]

  • 31. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K, Henne C, Odeyemi I, Pöhlmann J, Ahmed W, Pollock RF.
    J Med Econ; 2023 Jun 15; 26(1):411-421. PubMed ID: 36897006
    [Abstract] [Full Text] [Related]

  • 32. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y.
    Eur Urol; 2009 Jun 15; 55(6):1386-95. PubMed ID: 19193487
    [Abstract] [Full Text] [Related]

  • 33. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA.
    Urology; 2008 Feb 15; 71(2):297-301. PubMed ID: 18308107
    [Abstract] [Full Text] [Related]

  • 34. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients.
    Palou J, Angerri O, Segarra J, Caparrós J, Guirado L, Diaz JM, Salvador-Bayarri J, Villavicencio-Mavrich H.
    Transplantation; 2003 Nov 27; 76(10):1514-6. PubMed ID: 14657696
    [Abstract] [Full Text] [Related]

  • 35. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
    Leblanc B, Duclos AJ, Bénard F, Valiquette L, Paquin JM, Lapointe S, Mauffette F, Pharand D, Faucher R, Drouin G, Perreault JP.
    Can J Urol; 2000 Feb 27; 7(1):944-8. PubMed ID: 11121250
    [Abstract] [Full Text] [Related]

  • 36. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 27; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 37. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P, Turkeri L.
    Arch Esp Urol; 2013 Nov 27; 66(9):833-40. PubMed ID: 24231293
    [Abstract] [Full Text] [Related]

  • 38. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S, Nagata M, Takayama T, Ozono S, Ito T, Maruyama S, Hadano S, Nagae H.
    Hinyokika Kiyo; 2004 Jul 27; 50(7):469-73. PubMed ID: 15334890
    [Abstract] [Full Text] [Related]

  • 39. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar 27; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 40. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
    Witjes JA, Hendricksen K.
    Eur Urol; 2008 Jan 27; 53(1):45-52. PubMed ID: 17719169
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.